3 completed, 1 recruiting, 1 terminated, 1 unknown. 6 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 3, Recruiting 1, Terminated 1, Unknown 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Aphasia, Primary Progressive: new trials by email Literature Review of Aphasia, Primary Progressive trials Research Report on Aphasia, Primary Progressive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN) Intrathalamic AAV.PGRN administration, Intrathalamic AVB-101 - Frontotemporal Dementia, FTD | Phase 1 / Phase 2 | Recruiting | AviadoBio Ltd | 18 | 2023-08-30 | 2026-08-13 |
| BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TES BIIB092, Placebo - Primary Tauopathies, Corticobasal Degeneration Syndrome | Phase 1 | Terminated | University of California, San Francisco | 22 | 2018-09-12 | 2019-12-19 |
| A 24-month Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia AADvac1 40 µg, AADvac1 160 µg - Primary Progressive Nonfluent Aphasia | Phase 1 | Unknown | Axon Neuroscience SE | 33 | 2017-07-31 | 2019-11-14 |
| Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia and Frontotemporal Dementia F-18 AV 1451 - Primary Progressive Aphasia, Behavioral Variant of Frontotemporal Dementia | Phase 1 | Completed | Mayo Clinic | 81 | 2016-07-01 | 2025-11-21 |
| PiB PET Scanning in Speech and Language Based Dementias C-11 PiB, F-18 FDG - PPA, Primary Progressive Aphasia | Phase 1 | Completed | Mayo Clinic | 168 | 2010-03-01 | 2015-12-22 |
| Davunetide (AL-108) in Predicted Tauopathies - Pilot Study davunetide (AL-108, NAP), Placebo nasal spray - Predicted Tauopathies, Including, Progressive Supranuclear Palsy | Phase 1 | Completed | University of California, San Francisco | 12 | 2010-01-01 | 2019-04-05 |
Primary Progressive Nonfluent Aphasia (4) · Frontotemporal Dementia (3) · Pick Disease of the Brain (3) · Aphasia (1) · Aphasia, Broca (1) · Apraxias (1) · Color Vision Defects (1) · Corticobasal Degeneration (1) · Dementia (1) · Frontotemporal Lobar Degeneration (1) · Language (1) · Supranuclear Palsy, Progressive (1) · Tauopathies (1)
Brain Diseases (6) · Central Nervous System Diseases (6) · Communication Disorders (6) · Language Disorders (6) · Mental Disorders (6) · Nervous System Diseases (6) · Neurobehavioral Manifestations (6) · Neurocognitive Disorders (6) · Neurologic Manifestations (6) · Pathological Conditions, Signs and Symptoms (6) · Signs and Symptoms (6) · Speech Disorders (6) · Aphasia (5) · Dementia (5) · Frontotemporal Lobar Degeneration (5)
2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole (1) · AADvac1 (1) · davunetide (1) · gosuranemab (1)
Mayo Clinic (2) · University of California, San Francisco (2) · AviadoBio Ltd (1) · Axon Neuroscience SE (1)
United States (5) · Belgium (1) · Canada (1) · Germany (1) · Italy (1) · Netherlands (1) · Poland (1) · Spain (1) · Sweden (1) · United Kingdom (1)
Adam Boxer, MD, PhD (1) · Adam L. Boxer, M.D., Ph.D. (1) · Keith A Josephs, M.D. (1) · Keith A Josephs, M.D. MST, MSc (1) · Markus Otto, Prof (1)
2017 (1), 2023 (1), R21NS094684 (1)